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                                        INTRODUCTION 
 Pregnancy is a condition where the metabolic adaptations occur to 
accommodate rapidly growing tissue transplant, conceptus. Placenta, new 
organ arises de novo during the pregnancy, develops and matures till it is 
expelled at the completion of gestation. The conceptus for its own normal 
development causes alteration in the maternal metabolism characterized by 
hyperinsulinemia, low fasting and postprandial blood sugar levels when 
compared to the non pregnant state. The placenta facilitates embryogenesis, 
growth maturation and synthesis of peptide and steroid hormones and 
transport of fuel to the fetus from the mother. Thus metabolism in normal 
pregnancy is characterized by facilitated action of insulin in the first half of 
pregnancy and diabetogenic stress in the second half of pregnancy. 
 Gestational diabetes mellitus is defined as carbohydrate intolerance of 
variable severity resulting in hyperglycemia with the onset or first 
recognition during pregnancy. This is applicable regardless of the patient 
whether they are on insulin or only on diet modification.  
GDM represents an unidentified pre existing disease or because of the stress 
in pregnancy leading to a compensated metabolic abnormality which is 
unmasked or a direct consequence leading to altered maternal metabolism in 
pregnancy. Thus importance of GDM lies in fact that it is associated with 
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higher risk of type 2 diabetes in their later life in future. Most women control 
blood sugar with medical nutritional therapy and moderate exercise but who 
fail to control blood sugar needs anti diabetic medication like insulin.  
       Gestational diabetes is diagnosed by screening all the pregnant women 
during the pregnancy because GDM generally have few or no symptoms. 
High level of glucose in the blood samples is detected inappropriately by the 
diagnostic test. Depending upon the population studied, 3 to 10% of 
pregnancies are affected by GDM. 
         Babies born to mothers with gestational diabetes mellitus have 
increased risk for macrosomia, hypoglycemia, respiratory distress, still birth, 
hypocalcemia, shoulder dystocia, seizures, hyperbilirubinemia, intrauterine 
death, perinatal morbidity. Women with adequate blood glucose control can 
decrease the risk of adverse neonatal outcomes when gestational diabetes are 
treated effectively. These offspring are more prone for developing obesity in 
childhood and type 2 diabetes in their later life.  
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AIM OF STUDY: 
- To determine the perinatal outcome in relation to maternal fasting and 
postprandial (2 hours) blood sugar control in gestational diabetes mellitus.  
- Perinatal outcomes included are macrosomia, Respiratory distress 
syndrome, hypoglycemia, seizures, hyperbilirubinemia, NICU admission, 
Anomaly, IUD, Stillbirth, perinatal injury, perinatal mortality. 
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 REVIEW OF LITERATURE  
          Pregnancy is a physiological event in which there is a progressive 
change in the carbohydrate metabolism in mother. As the pregnancy 
advances, there is compensatory increase in insulin secretion due to 
diabetogenic stress and increase in insulin resistance due to placental 
hormones. When this compensation is inadequate, gestational diabetes 
develops.  
          GDM is associated with increased perinatal mortality and morbidity 
when blood sugar is not under control. So universal screening for the 
detection of carbohydrate intolerance in pregnancy is recommended. 
Treatment depends upon the degree of glucose intolerance. 
         So by early and routine screening for all pregnant mother and treating 
mothers with GDM can reduce the perinatal mortality and morbidity.  
DEFINITION 
       Gestational diabetes is defined as carbohydrate intolerance of varying 
severity with the onset or first recognition during pregnancy. This is 
applicable regardless of the patient whether they are on insulin or not.  
(American diabetic association). (1) 
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CLASSIFICATION 
       Classification aids in the diagnosing the severity of diabetes and to plan 
the management and to assess the prognosis of the mother and fetus. 
      Priscilla Whites classification (2) on perinatal outcome is based on the 
diabetes type, age of onset, duration of diabetes and its complications.  
      It distinguishes GDM [type A] from the overt diabetes. These two groups 
are divided further based on their associated risk and management. (3) 
PRISCILLA WHITES CLASSIFICATION  
CLASS A: 
 Type A1:  
Abnormal oral glucose tolerance test followed by fasting and 2- hr post 
prandial blood sugar levels are normal. So blood sugar levels are maintained 
by dietary modification. 
Type A2: 
 Abnormal OGTT followed by elevated fasting and 2- hr post prandial blood 
sugar levels. So insulin is needed along with diet modification.  
CLASS B: Age of onset >  20 Years, short duration  < 10 years 
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CLASS C: Age of onset 10 – 19 years, duration of 10 – 19 years 
CLASS D: Age of onset under 10 years, duration > 20 years, background 
retinopathy  
CLASS F: Nephropathy with over 500 mg/day proteinuria 
CLASS H: Clinically evident atherosclerotic heart disease  
CLASS R: Vitreous hemorrhage or proliferative retinopathy 
CLASS RF: Criteria for both class R and F coexists 
CLASS T: Prior renal transplant 
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ACOG CLASSIFICATION OF DIABETES COMPLICATING 
PREGNANCY  
Class Onset Fasting 
plasma 
glucose 
2- hr PPBS Therapy 
A1 Gestational <105 
mg/dl 
<120 mg/dl Diet 
A2 Gestational >105 
mg/dl 
>120 mg/dl Insulin 
CLASS Age of 
onset 
Duration Vascular 
disease 
Therapy 
B >20  <10 None Insulin  
C 10 - 19 10 - 19 None Insulin 
D Before 10 >20 Benign 
retinopathy 
Insulin 
F Any Any Nephropathy Insulin 
R Any Any Proliferative 
retinopathy 
Insulin 
H Any Any Heart Insulin 
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PATHOPHYSIOLOGY 
       Effects of insulin on glucose uptake and metabolism: 
 1. Insulin attach to its receptors on cell membrane and causes activation of 
many protein cascades. 2. Translocation of GLUT-4 transporters to the 
plasma membrane and causes influx of glucose. 3. Promotes glycogen 
synthesis, glycolysis and fatty acid synthesis.  
       The hallmark in pathogenesis of GDM is increased insulin resistance. 
Pregnancy hormones and other factors bind to insulin receptor and interfere 
with action of insulin. This interference occurs behind the insulin receptor at 
the level of cell signaling pathway. Entry of glucose into the cells is 
promoted by insulin whereas in insulin resistance proper entry of glucose into 
the cells is prevented. As a result, blood sugar levels are elevated. More 
insulin is needed to overcome the resistance. So insulin is produced about 1.5 
to 2.5 times higher than in normal pregnancy.(4)  
     The metabolic changes occurring in normal pregnancy are essential for 
supplying the nutrients to the growing fetus. As pregnancy advances, 
increased level of human sommatomammotrophin, cortisol , prolactin, 
progesterone and oestrogen leading to insulin resistance in peripheral tissues. 
Normally in pregnancy insulin resistance starts in the second trimester and 
17 
 
progresses to the level as that occurs in women with type 2 diabetes who are  
non pregnant. 
      The reason is not known why some of the patients are not able to balance 
the insulin needs and develop gestational diabetes. Reasons are given similar 
to those in type 2 diabetes mellitus. Autoimmunity, obesity, single gene 
mutation and other mechanisms.(5) 
     Glucose travels across the placenta by GLUT3 carriers by the process of 
facilitated diffusion. Therefore fetus is exposed to high blood glucose level 
and thus causing increased insulin secretion in the fetus. The growth 
stimulating effects of insulin leads to excessive growth and macrosomia in 
the fetus. After birth blood sugar levels are low with high insulin production 
leading to hypoglycemia. (6) 
SCREENING IN PREGNANCY 
Need for screening 
- Majority of the patients with mild carbohydrate intolerance do not have 
any signs and symptoms. 
- Routine blood and urine tests are not reliable for diagnosing GDM. 
- Glucose intolerance in pregnancy leads to significant increase in 
maternal morbidity and fetal mortality and morbidity. 
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- So early diagnosis and treatment is essential to prevent mortality and 
morbidity. 
POPULATION TO BE SCREENED 
      Early screening for glucose intolerance results in the reduction of some 
complications due to hyperglycemia.(7) Screening done in the third trimester 
results in delivering big baby in large number of pregnant women despite 
good control of blood sugar.(8) So early screening is essential. 
      The ideal time for screening is around 16 weeks of gestation and should 
be done earlier in the people with high risks.(9) Insulin is detected in fetal 
pancreas at 9 weeks of gestation. By16th week, pancreatic cell mass increase 
in the fetus leading to increase in insulin secretion in response to maternal 
hyperglycemia.(10) This priming of beta cells in fetus accounts for persistence 
of fetal hyperinsulinemia throughout pregnancy resulting in fetal growth 
acceleration even when the mother has good blood sugar control in later part 
of pregnancy.(11)  
   Therefore screening should be started in first trimester itself to diagnose 
GDM. Early detection and care result in better outcome of fetus .(12)  Pregnant 
women having normal glucose tolerance in the first trimester should be 
screened again at 24th – 28th week of gestation and again at 32nd -34th week of 
gestation if it is normal in second trimester.(13) 
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Universal screening - It is practiced in high risk population who are more 
prone to develop type 2 diabetes mellitus. 
High risk screening - It is done for the patients with the following risk factors 
as recommended by ACOG.    
Risk factors for screening  
- Age > 25 years 
- Obesity 
- Ethnic group people with a high prevalence for GDM 
- History of macrosomia , congenital anomalies in the previous pregnancy, 
stillbirth, IUD 
- Family history of diabetes 
- Previous unexplained neonatal death 
- History of GDM or PIH in previous pregnancy 
- History of recurrent spontaneous early pregnancy loss  
- History of recurrent UTI and moniliasis 
- History of polyhydramnios in previous pregnancy 
- Glycosuria 
- History of preterm labor and delivery 
  35 – 50% of women with GDM will not have any of the above risk factors. If 
high risk screening methods are used, 35 – 50% of diabetic patients will be 
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missed.(14) Universal screening detects higher number of cases when compared 
to selective screening and improving the maternal and fetal prognosis.(15) 
ACOG recommends selective screening in some settings and universal 
screening in high risk groups. In a study done in south India, it was found that 
when screening is based on historical risk factors alone, 45.4% of the pregnant 
women remain unscreened. Among the unscreened population, 35% had 
abnormal glucose tolerance.(16) So American Diabetic Association recommends 
universal screening for all the patients. Indian women have high prevalence of 
developing gestational diabetes among the ethnic group in South Asian 
countries.(17) Indian women have 11 fold increased risk for developing glucose 
intolerance in pregnancy when compared with Caucasians.(18) So in India 
screening is recommended for all the pregnant women. 
METHODS OF SCREENING 
      Various screening methods are available to screen gestational diabetes. 
1) Glucose challenge test 
      This test is adopted by O’ Sullivan and co-workers as a screening test in 
1973. 50 gm of glucose in 200 ml of water was given to the patient 
irrespective of time of last meal or time of the day. Venous blood was drawn 
after one hour and the plasma glucose level is estimated. The recommended 
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threshold is 140 mg/dl for this test. It has sensitivity of 80% and specificity of 
90%. The sensitivity is increased to 90% if the cut off is taken as 130 mg/dl. 
    Therefore 50 gm of glucose tolerance test is the best and reliable screening 
test for gestational diabetes.(19,20) This test is performed soon after the  
pregnancy is diagnosed in high risk patients. If the test is negative, repeat 
again at 24 to 28 weeks of gestation. For the low risk patients it is done 
between 24 to 28 weeks of gestation. When one hour blood glucose value is 
more than 200mg/dl, these patients are diagnosed to have GDM directly and 
followed with fasting and postprandial blood glucose levels. 
2) WHO testing 
     75 gm of glucose load was given and plasma glucose was estimated after 
2 hours. Pregnant women need not be in fasting state.(21) When the plasma 
glucose concentration is more than 140 mg/dl, it  is diagnosed as GDM. It is  
one step procedure and serve both as the screening and diagnostic procedure. 
This test is simple, feasible and economical.(22) 
3) Fasting blood sugar:    
Fasting blood sugar in normal pregnant women will be around 70- 90 mg/dl. 
If it is > 105 mg/dl suggests glucose intolerance. Only 1/3rd of GDM patients 
will have fasting hyperglycemia. If fasting blood sugar is taken as screening 
test remaining 2/3rd GDM patients are not diagnosed.(23) When fasting blood 
sugar level is more than 126mg/dl, the patient is diagnosed as GDM and no 
need for glucose tolerance test.(1) 
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4) Post prandial blood sugar 
     Many patients experience nausea and vomiting with 50 gm of glucose. To 
improve the compliance and decreasing the side effects various studies are 
done using various substrates and reported to be adequate substitutes of 
glucose.  
     Coustan DR et al (24) in 1987 examined test efficacy of a standardized 
nutrient meal (600 Kcal) given to 20 women with GDM in the early trimester 
and 50 presumed normal pregnant women in the fasting state. This test shows 
sensitivity of 75% and specificity of 94%. Similar study was conducted by 
Ginecol obstet Max in 2002(25) and concluded similar results and proved that 
one hour postprandial test was as effective as 1 hour glucose challenge test. 
5) Random plasma glucose estimation 
      Levin et al found an incidence of 1.5% GDM in patients with high risk 
using random plasma glucose as a screening test. Nasart et al(26) suggested 
plasma blood glucose estimation is insensitive for identifying GDM with 
sensitivity of 65%. 
6) Seshiah spot test 
       Seshiah et al (27) suggest single glucose challenge test with 75 gm of 
glucose for universal screening and diagnosis. Plasma blood sugar is taken 
after 2 hours. If the value is > 140mg/dl, diagnosed as GDM.  
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7) Glycosylated HbA1C 
        HbA1C- a glucose molecule is attached to N- terminal group of beta 
chain of hemoglobin by a non enzymatic reaction and the attachment depends 
on concentration of sugar in the blood over a period of time, 3 months. 
According to the studies (28) HbA1C is a poor test to screen for GDM. This test 
is used in overt diabetes to predict the risk of embryopathy.(29) 
8) Serum Fructosamine 
       Fructosamine is associated with glycemic control over the past 1 – 3 
weeks. But this test is less sensitive for screening than glucose challenge 
test.(30) Hoffman et al (31) suggested that it can be used to detect fetal 
hyperinsulinemia in women with gestational diabetes. When maternal 
fructosamine is > 2.6 mmol, it indicates fetal hyerinsulinemia. 
9) Urine Sugar Test 
       In pregnancy renal threshold for glucose excretion is decreased due to 
increase in glomerular filtration rate of glucose and intermittent tubular defect 
in absorption of glucose.  The specificity of glucosuria is increased by 
determining significant glucosuria occurring in the second morning fasting 
urine specimen. Pregnant women with glucosuria are more prone to develop 
preterm labour (25%) and fetal macrosomia (7%).(32) 
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DIAGNOSIS OF GESTATIONAL DIABETES 
      One Step Approach – Diagnostic 100 gm oral glucose tolerance test is 
done with no prior screening test. It is less costly and used in population with 
higher risk.  
      Two Step Approach – Initial screening test is done by using 50 gm of oral 
glucose and one hour plasma glucose concentration is estimated. Diagnostic 
100 gm oral glucose tolerance test is performed on those women with elevated 
blood glucose threshold levels on GCT. 
GLUCOSE TOLERANCE TEST: 
- 100 gm 3 hour OGTT 
- 75 gm 2 hour OGTT – WHO 
100 gm Oral Glucose Tolerance Test: 
      Patient is instructed to have unrestricted diet of  >150 gm of carbohydrate 
per day , unrestricted physical activity for three days before the test and 
advised to come with overnight fasting of  at least 8 hours but not more than 
14 hours.(33) The subject remains seated and not to smoke during the test. FBS 
is taken and patient is advised to drink 100 gm of glucose dissolved in 300 ml 
of water. Hourly blood sample and urine samples are taken for three hours.  
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Diagnostic criteria for 100 gm OGTT  
Timing of 
measurement 
National diabetes 
and data groups (in 
mg/dl) 
Carpenter and 
Coustan (in mg/dl) 
Fasting  105 95 
1 hour  190 180 
2 hours 165 155 
3 hours 145 140 
    The cut off values recommended by Carpenter and Coustan (34) for the 
extrapolation of blood sugar values was found by O’ Sullivan and Mahan (35) 
for glucose concentrations in plasma. When one value is elevated patient is 
diagnosed to have impaired glucose tolerance. When two or more values are 
elevated, patient is diagnosed to have gestational diabetes. 
75 gm Oral Glucose Tolerance Test:   Sack’s recommendation (36) 
Time  Mg/dl Mmol/L 
Fasting  95 5.3 
One Hour  180 10.0 
Two Hours 155 8.6 
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WHO Diabetes Criteria 2006 
Condition Fasting blood 
glucose levels ( in 
mg/dl ) 
2 hours blood  
glucose levels ( in 
mg/dl) 
Normal <110 <140 
75 gm of oral glucose load >126 >140 
Impaired fasting glycemia 110 to 125 <140 
Impaired glucose tolerance <126 >140 and < 200 
Diabetes mellitus >126 > 200 
      GDM is diagnosed based on 2 hours 75 gm of oral glucose tolerance test as 
defined by either WHO criteria or ADA predicts the adverse pregnancy 
outcomes equally.(37)  
Intravenous Glucose Tolerance Test: 
       In this method 0.5 mg of glucose per kg of ideal body weight is 
administrated intravenously over 2 minutes. Blood glucose estimation is made 
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before the injection and at 10 minutes interval for the following hour. These 6 
plasma glucose determinations are used to construct a graph. The time taken 
for blood glucose to fall to half of its value is used to calculate the absolute 
glucose disappearance rate K.(38) 
K value is calculated as  
K = (0.693/ t ½) * 100 
K < 1.5 – abnormal glucose tolerance 
The lower limit of normal value of K in first trimester is 1.37, second trimester 
is 1.18 and third trimester is 1.13. Value below this level is regarded as 
abnormal.  
The oral test is practical for outpatient and it is better in estimating the 
efficiency of glucose disposal in patients with mild abnormalities in glucose 
intolerance. 
Intravenous glucose tolerance test is useful in patients with gastrointestinal 
disorders. The K values allow easier method for analysis of glucose tolerance 
and in most circumstances, it is independent of blood glucose measurements 
whatever may be the method of test. It is unaffected by variations in gastric 
emptying and the phenomenon may vary from patient to patient. But 
intravenous glucose tolerance is more expensive and is non physiological.  
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For universal screening Seshiah et al (27) suggested that a single glucose 
challenge test with 75 gm of oral glucose load and when 2 hour plasma venous 
sample is  > 140 mg/dl, it is diagnosed to have GDM,  > 120  and < 139 mg/dl 
diagnosed to have gestational glucose intolerance,  > 200 mg/dl labeled as 
overt diabetes. This method is recommended by WHO, because of single step 
procedure and it is used for both screening as well as diagnostic test. It is 
simple to perform and it is less costly. 
NEONATAL OUTCOME  
    Fetus of diabetic mothers have  wide range of structural and biochemical 
abnormalities that can be reduced or eliminated by improving the control of 
blood sugar metabolism.  
Macrosomia : 
        Neonate weighing more than 4.5 kg. In Indian consensus newborn > 4 
Kg is considered as macrosomia .The reason behind it is fetal 
hyperinsulinemia. Pedersons hypothesis states that increased maternal blood 
glucose results in increased fetal blood glucose levels which in turn 
stimulates the pancreatic fetal cells to produce large amount of insulin which 
is one of the main growth factor for fetal tissue (Pedersen J, 1967) (39) 
       Insulin has growth promoting effects by diverting the cell metabolism 
into anabolic process like lipogenesis , glucogenesis and protein synthesis. It 
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also influences other endocrine systems to produce other growth factors to 
stimulate the growth.  
       There is a continuous association of maternal blood glucose level with 
increased birth weight of baby. The incidence of macrosomia is decreased 
when blood sugar is under control.(40) The incidence of shoulder dystocia, birth 
injuries , neonatal morbidity and asphyxia (41) are increased in macrosomic 
babies. The risk of birth trauma is more in infants weighing > 4.5 kg .(42) 
Women with elevated fasting and normal postprandial blood sugar values are 
having the infants at increased risk of  macrosomia. 
HYPOGLYCEMIA:   
           Due to endogenous hyperinsulinemia and suppression of endogenous 
glucose production, the infants are at increased risk of hypoglycemia at 1- 3 
hours of birth.(43) Neonatal hypoglycemia is due to hyperplasia of pancreatic 
beta cells of the fetus and the increased maternal substrate delivery to the fetus 
as proposed by Pederson et al. (39)After birth, glucose which is supplied 
continuously from the mother is stopped, so neonate is more prone to develop 
hypoglycemia due to insufficient delivery of the substrate. Perinatal stress due 
to release of cathecolamine and depletion of glycogen makes the neonates for 
further development of hypoglycemia. 
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          50% of babies are asymptomatic. Symptoms of hypoglycemia include 
irritability, jitteriness, high pitched or weak cry, apathy, poor feeding, 
hypotonia or seizures. Hypoglycemia which requires intervention may be 
persisted for one week or longer resulting in increased neonatal intensive care 
admission and prolonged hospital stay in neonates.(44) 
        The incidence of hypoglycemia is high in infants whose mothers had a 
longer duration of diabetes.(45) Hypoglycemia is defined as when blood sugar 
level is lower than 45 mg/dl but the precise level remain controversial. 
Thershold levels was proposed by Cornblath et al.(46)  
Blood sugar measurements are done  
- As soon as after birth 
- At any time clinical signs are observed 
- Two to three hours after birth and before feeding 
Treatment of Hypoglycemia : Immediate 2 ml/kg of IV 10% dextrose 
infusion is administrated over 5- 10 minutes. Maintenance dose of dextrose 
is done at an infusion rate of 6- 8 mg/kg/min after the bolus. This is done to 
prevent rebound hypoglycemia. Blood glucose is measured to properly 
titrate the dextrose infusion. Once blood sugar levels are stable for 12 
hours, dextrose is tapered by 1-2 mg/kg/min and the blood sugar is 
maintained above 45 mg/dl. 
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HYPOCALCEMIA: 
          Defined as serum calcium < 7.5 mg/dl.(47) Asphyxia and prematurity 
increases the level of cortisol which is a vitamin D antagonist at the intestinal 
level. Respiratory distress and fetal metabolic acidosis results in shifting of 
calcium from intracellular to extracellular pool and the reversal occurs during 
the correction of acidosis causing hypocalcemia. Hypocalcemia is also 
associated with delay in parathyroid hormone synthesis after birth. 
        Symptoms includes jitteriness or seizure activity.(48) True hypocalcemia is 
very rare. In most cases, symptoms caused due to lower level of calcium are 
mainly due to low blood glucose levels. Hypocalcemia are treated by diluting  
calcium gluconate to IV solution of dextrose to deliver at a rate of 600- 
800mg/kg/day.(49) Hypomagnesemia may coexist and may require correction. 
RESPIRATORY DISTRESS SYNDROME: 
        Insulin antagonizes the stimulatory effects of cortisol on fibroblast to 
induce the synthesis of fibroblast pneumocyte factor. This inhibits 
phosphotidyl choline production on type 2 pneumocyte cells 
- Hyperglycemia 
- Decreases the bioavailability of important precursors for phospholipids 
production and surfactant protein modification. 
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- Decrease the number of type 2 laminar bodies and alveolar cells.  
- Decrease the production of phosphotidyl cholines and phosphtidyl  
glycerol 
RDS presents after the birth shortly and manifested as tachypnea, chest wall 
retractions, tachycardia, grunting and nasal flaring and may have cyanosis. 
Most infants with respiratory distress born to GDM mothers were unrelated 
to surfactant deficiency.(50) 
Neonates of the mothers with GDM experiences respiratory distress 
syndrome even if they are term.(51) Some studies suggested that prenatal 
steroid administration at 37 to 38 weeks of gestation, 48 hours before 
elective cesarean section reduces the incidence of transient tachypnea of 
newborn but this is not commonly done.(52)  
Transient tachypnea of the newborn (TTN) is a parenchymal disorder of 
lung which occurs due to the delayed absorption and clearance of alveolar 
fluid. Respiratory distress due to TTN is most common in term GDM 
neonates. TTN is more common in elective cesarean section due to lack of 
exposure to uterine contractions.(53) 
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HYPERBILIRUBINEMIA: 
 It occurs due to the increased production and decreased life span of RBC’s 
with glycosylated cell membranes.(54) Hepatic conjugation of bilirubin may be 
impaired due to immaturity of liver and deficiency of glucuronyl transferase 
enzyme. Hyperbilirubinemia is more common in association with 
polycythemia. It is more common in GDM neonates compared to general 
population.(49) 
Women with normal fasting and elevated postprandial blood sugar values are 
having the infants at increased risk of  hyperbilirubinemia.(55)  It is found with 
increased frequency in macrosomic infants of GDM mothers.(56) Neonates with 
elevated bilirubin are treated with phototheraphy.(57) 
POLYCYTHEMIA: 
 Polycythemia is defined as peripheral venous hemotocrit is > 65 %. It occurs 
due to hypoxic stimulus by the placental insufficiency and elevated 
glycohemoglobin.(58) The resultant hyperviscosity may induce congestive 
cardiac failure and vascular thrombosis. Polycythemia is observed more 
frequently in infants of GDM mothers. Large for gestational age infants are at 
greater risk for polycythemia in the early neonatal period.(59) The incidence of 
polycythemia is 1% - 5%. 
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INTRAUTERINE DEATH/ STILL BIRTH: 
Usually occurs after 36th week of gestation in gestational diabetes.(60,61) Causes 
are chronic intrauterine hypoxia with acidosis,(62) high fasting blood sugar 
levels, placental dysfunction and competition for essential nutrients.(63) Women 
with gestational diabetes are in high risk category for fetal death. Therefore 
intensive monitoring is essential with the consideration for timed delivery.(64) 
EARLY PREGNANCY LOSS: 
Early spontaneous pregnancy loss are more common in women with 
hyperglycemia in periconceptional period and in the first trimester.(65) More 
common in diabetes complicating pregnancy with poor blood sugar control. 
PRETERM BIRTH: 
Preterm delivery may be either spontaneous or iatrogenic done for some 
maternal or fetal indications. It occurs more common in women with type 1 
diabetes mellitus.  Spontaneous preterm labor or premature rupture of 
membranes are due to poor blood glucose control.(66) Indicated preterm 
delivery is due to increased occurrence of preeclampsia. 
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CONGENITAL ANOMALIES: 
The incidence of congenital anomalies is more common in overt diabetes.  The 
abnormalities arise as a consequence of poor glycemic control 
periconceptionally and during embryogenesis.(67) Incidence of congenital 
malformation is 5 –10 %.(68) 
- Overt diabetes  -  10.1 % 
- Gestational diabetes  -  4.8 % 
- Normal population  -  2% 
ANOMALIES: 
CVS: 
 - Transposition of great arteries 
- Atrial septal defect 
- Hypoplastic left ventricle 
- Ventricular septal defect 
- Anomalies of aorta 
- Situs inversus 
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CNS 
- Holoprocencephaly 
- Encephalocele 
- Anencephaly 
- Meningomyelocele 
SKELETAL & SPINE 
- Spina bifida 
- Caudal regression syndrome 
GENITOURINARY 
- Renal agenesis 
- Polycystic kidneys 
- Ureteral duplication 
GASTROINTESTINAL 
- Tracheo-oesophageal fistula 
- Bowel atresia 
- Imperforate anus 
The most frequent anomaly involves the heart and CNS. Anomalies are more 
common in overt diabetes. 
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MATERNAL OUTCOME: 
Complications develop when blood sugar is not under control during 
pregnancy. Maternal infections are more common in diabetes. Preeclampsia (69) 
and polyhydramnios are the antenatal complications commonly arise. As a 
result of this, patients are more prone for preterm delivery.  
Approximately 20% of diabetic mothers who deliver vaginally suffer perineal 
tears. Langer (70) reported the incidence of shoulder dystocia is 0.3% when 
birth weight of the baby is less than 4.0 kg and increased to 4.9% when the 
birth weight is more than 4.0 kg. Non diabetic women had 0.5% of shoulder 
dystocia when compared to diabetic women who had risk of 3.25%. 
Complications occurring secondary to a delivery of macrosomic baby (71) are 
an increased rate of caesarean delivery, shoulder dystocia, birth trauma and 
postpartum hemorrhage. 
MANAGEMENT: 
The main aim of treatment is to decrease the risk for both mother and fetus. By 
good glycemic control, we can reduce the fetal complications and improve the 
maternal quality of life. Unfortunately more newborns of GDM mothers are 
admitted in NICU and there is increased induction in labor, with no proven 
reduction in rates of cesarean section or neonatal mortality.(71) They are still in 
recent research and controversial.(72) 
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Specific blood sugar values are used as targets in the treatment that maintain 
capillary blood sugar levels within the normal range. ACOG guidelines 
recommends to maintain fasting blood sugar <95 mg/dl, one hour postprandial 
blood glucose < 140 mg/dl an 2 hour postprandial blood glucose < 120 mg/dl. 
Guidelines suggested by Jovanovic – Peterson et al(73) are little stricter to 
maintain FBS < 90 mg/dl and 2 hour PPBS < 120 mg/dl. 
MEDICAL NUTRITION THERAPY: 
       The goal of medical nutrition therapy is to provide adequate calories and 
nutrients for the mother as well as the fetus, for appropriate maternal weight 
gain and to achieve the normal blood glucose levels so that starvation and 
ketosis can be avoided. In the first trimester of pregnancy, usually there will be 
no increased energy requirements. Whereas in second and third trimester, 
additional calories of 300 K cal/day are required in pregnant women with 
normal weight. There is no need for hospitalization in women with GDM for 
dietary advice and further management if there is good glycemic control.(74) 
       In women with GDM of normal weight, 30 kcal/kg/day is recommended 
daily based on their present pregnancy weight. In case of overweight women 
with GDM of BMI >30 kg/m2, daily calorie intake is restricted to 25 
Kcal/kg/day based on their present pregnant weight. This limitation of calorie 
restrictions are not usually associated with increased levels of free fatty acids 
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or ketonuria. However to prevent ketosis adequate measures are taken. More 
aggressive restriction of calories results in ketosis.(75) 
  Carbohydrate is divided throughout the day into three snacks and three small 
to moderate sized meals. When carbohydrates are restricted to 40% of total 
daily caloric intake, the postprandial blood glucose levels are decreased. 
Therefore when carbohydrates with low glycemic index are consumed 
especially in late gestation, it causes reduction in the postprandial blood sugar.  
  Individualization of medical nutritional therapy is done depending upon the 
height and weight of the mother as recommended by American diabetic 
association. Continuous monitoring of blood sugar level is required whether 
blood sugar level is well controlled with diet. Fasting and postprandial blood 
sugar levels are measured weekly and then biweekly. 
EXERCISE: 
 Women with GDM are encouraged to have an active life style which should 
include some exercises. Walking briskly for 30 to 40 minutes per day will 
improve the glycemic control. Upper limb exercises are recommended if the 
patient is not permitted for walking. ADA recommends starting or continuing 
the exercise in GDM women with no medical or obstetrical contraindications. 
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INSULIN: 
 It is a pharmacological therapy and it reduces fetal morbidities when added 
along with medical nutrition therapy. When medical nutrition therapy fails to 
maintain the self monitored blood glucose at the following levels, insulin is 
recommended.(76) 
- Fasting blood glucose  > 95 mg/dl. 
- 1-hr postprandial blood glucose > 140 mg/dl. 
- 2-hr postprandial blood glucose  > 120 mg/dl. 
The GDM women need hospitalization to safely titrate dosage and to educate 
her on self administration of insulin and monitoring the blood glucose levels. 
To start with, premix insulin 30/70 is better preferred.(8)  
- Starting dose of insulin is  4 units before the breakfast 
- If blood glucose level is not under control, the dose of insulin is 
increased to 2 units till 10 units every 4th day. 
- If FBS is >90 mg/dl, 6 units prior to breakfast and 4 units prior to dinner 
is used.  
- Blood glucose is repeated and doses of insulin are adjusted according to 
the blood glucose levels. 
- Total dose of insulin is divided per day, 2/3rd of the dose is given in 
morning and 1/3rd of the dose is given in evening. 
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- When initial postprandial blood sugar level is high, premix 50/50 is 
started. 
- If 2-hr postprandial blood sugar is > 200 mg/dl at the time of diagnosis, 
starting dose of insulin is 8 units before breakfast is recommended and 
the dose is titrated according to the blood sugar level. 
When GDM is diagnosed in the third trimester of pregnancy, patient is advised 
on medical nutrition therapy for one week. When MNT fails, insulin is used. 
Along with insulin, medical nutrition therapy is recommended. Patients 
difficult to control blood sugar levels with insulin may be benefited by insulin 
pump.  
Rapidly acting insulin analogs which are available currently are aspart, lispro, 
and glulisine. Glargine and detemir are the long acting insulin analogs. The 
insulin analogs are synthesized by recombinant DNA methods.  
Lispro, starts its action within 10 to 15 minutes of injection, reaching a higher 
peak concentration within 30 to 60 minutes and its action lasts for up to 3 to 4 
hours. Aspart is also similar to lispro but it takes a slightly longer time to reach 
its peak concentration of about 40 to 50 minutes and its duration of action is 
also slightly longer for 3 to 4 hours. Overall, when administrated 
subcutaneously, rapidly acting insulin analogs have very similar 
pharmacokinetic and pharmacodynamic actions. 
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 Human regular insulin has its onset of action within 30 to 45 minutes and its 
effect is prolonged for 2 to 3 hours, whereas rapidly acting insulin analogs 
have rapid onset of action, reaching their peak concentration earlier and its 
duration of action is briefer. So it is more similar to physiological dosing of 
insulin in lowering the post prandial hyperglycemia and avoids the late onset 
of hypoglycemia.(77)  
Glargine takes longer time to start its action (1.5 hours) when compared to 
ultralente insulin (1 hour) and NPH (0.8 hour). The duration of action for  
glargine remains longer for 20.5 hours whereas for NPH it about 13.2 hours 
and ultralent  is 19 hours. Currently aspart and lispro are the only insulin 
analogs which are classified as Category B drugs in pregnancy, which is in the 
same category risk as like that of regular insulin. 
Insulin dose is always individualized and needs to be adjusted according to the 
blood sugar levels. When the requirements for insulin falls, it may be due to 
placental insufficiency or fetal jeopardy or may be because of increased 
utilization of maternal glucose by beta cells of the pancreas in macrosomic 
fetus.(8) 
ORAL HYPOGLYCEMIC AGENTS: 
  ADA or ACOG does not recommend oral hypoglycemic agents in the 
pregnancy. The older groups of sulfonylureas such as tolbutamide and 
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chlorpropamide cross the placenta, stimulating the pancreatic beta cells of 
fetus to produce increased insulin secretion in the fetus resulting in neonatal 
hypoglycemia and may aggravate neonatal hyperbilirubinemia by competing 
for albumin binding sites.  
Glyburide is a long acting second generation sulfonyl ureas. It binds to 
sulphonyl receptor in the beta cells, stimulating the insulin secretion. It is used 
in patients with some amount of residual functions in beta cells of pancreas. 
Circulating blood glucose levels are lowered by 20% and it is used in the 
patients with normal or minimally increased body weight.  
 Elliott et al (78) found that there is minimal transfer of glyburide across the 
placenta. Mother who is on glyburide, cord blood of their offspring does not 
reveal the drug . But FDA does not approve gluburide for the treatment of 
gestational diabetes and more studies are needed to establish their safety in the 
future. 
 Metformin is a biguanide (Insulin sensitizer) belongs to category B drug. It is 
not used routinely in pregnancy. Studies have shown that women who continue 
metformin in pregnancy incase of polycystic ovarian syndrome or in type 2 
diabetes are found to have no adverse effects in their outcomes of pregnancy.  
However there is a clinical trial which is ongoing in New Zealand which 
compares metformin with insulin in women with gestational diabetes. 
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ANTEPARTUM FETAL ASSESSMENT: 
The method and frequency of fetal well being surveillance is determined by 
the level of maternal hyperglycemia and the presence of other associated 
adverse high risk factors.  
Antepartum fetal assessment as recommended by ACOG is done in women 
with poor glycemic control, who require insulin to control their blood sugar 
levels, with a history of hypertensive disorders and adverse obstetrical 
outcomes. The type of antepartum tests used for fetal surveillance is non stress 
test and biophysical profile. 
In women with well controlled diabetes, the role of antepartum fetal 
surveillance is not clear. Fourth International Workshop Conference on GDM 
recommends non stress test to start form 32 weeks of gestation in women on 
insulin and at or near term in those women with diet alone.(76) 
Women with gestational diabetes should be taught about the importance of  
monitoring  the fetal movements in the last 8 to 10 weeks of pregnancy and to 
report immediately when they have any reduction in the perceiving the fetal 
movements. 
Recent studies have shown the importance of role of ultrasound in the fetus to 
guide the management of the women with gestational diabetes. When 
ultrasound done at 30 weeks of gestation showed abdominal circumference of 
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the fetus is greater than 70th percentile, it is usually associated with increased 
risk of macrosomia . So ultrasound is done every 4 weeks starting from 20 
weeks of gestation. Therefore ultrasound play a major role in antepartum fetal 
assessment for further management in women with gestational diabetes.(69) 
PERIPARTUM CONSIDERATIONS: 
In women with gestational diabetes having good blood sugar control with no 
other complications, delivering the fetus before 40 weeks of gestation is not 
recommended.(79)  
Women with GDM on insulin require frequent antenatal testing and are 
managed in the same way as women with overt diabetes. Early delivery by 
induction is done. The time and route of delivery depends on the fetal 
condition. Macrosomia is less common in well controlled GDM.  
But according to American Diabetic Association, prolongation of pregnancy 
beyond 38 weeks of gestation increases the risk of macrosomia in the fetus 
without reduction in the rate of caesarean section, so delivery is done at 38th 
week. If a delivery is done before 39 weeks of gestation, lung maturity in the 
fetus is assessed by amniocentesis before induction of labor.(79)  
  Counseling is done in women in the presence of clinically and 
sonographically diagnosed macrosomia ( Fetal weight >4.5 kg) for elective 
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caesarean section  to avoid maternal and fetal trauma as recommended by 
ACOG.  
When the estimated weight of fetus is between 4.0 to 4.5 kg, and when there 
are additional risk factors for shoulder dystocia, clinical pelvic examination is 
done and the progress of labor is monitored carefully. Women past delivery 
history is also considered.(79) 
POSTPARTUM CONSIDERATIONS: 
Women with gestational diabetes are more prone to develop type 2 diabetes 
mellitus in the future. After the pregnancy, maternal glycemic status is 
reclassified at 6 weeks or more after delivery and followed every 3 years to 
detect impaired glucose tolerance, diabetes mellitus, impaired fasting glucose,  
or normoglycemia.  
Normal values for 2 hour OGTT are FBS <110 mg/dl and 2 hour post glucose 
load of 75 gm should be <140 mg/dl. Glucose values that meet the criteria for 
labeling as diabetes are FBS >126 mg/dl and 2-hr post glucose load is > 200 
mg/dl. 
 If the blood sugar values fall between these two thresholds they are labeled as 
impaired fasting glucose and impaired glucose tolerance. (ADA 2003)  
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5th International Workshop Conference: Metabolic assessments 
recommended in women with GDM after pregnancy. 
Time Tests Procedure 
Post delivery 
(1 to 3 days) 
Fasting or the random 
plasma glucose 
Detect persistent, overt 
diabetes 
Early postpartum 
( 6 to 12 weeks) 
75 gm with 2 hours OGTT Postpartum 
classification of glucose 
metabolism 
1 year postpartum 75 gm  with 2 hours OGTT Glucose metabolism is 
assessed 
Annually Fasting plasma glucose Glucose metabolism is 
assessed 
Tri anually 75 gm – 2 hours OGTT Glucose metabolism is 
assessed 
Prepregnancy 75 gm – 2 hours OGTT Classify glucose 
metabolism 
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LIFE STYLE: 
All women with history of gestational diabetes are educated about their life 
style modifications which lessen the insulin resistance that includes medical 
nutrition therapy, exercise, physical activity, maintaining normal body weight. 
Drugs which cause increased insulin resistance like steroids, nicotinic acid are 
better avoided. Women with GDM should be taught about the symptoms of 
hyperglycemia and to seek medical attention if they develop symptoms. 
 Recurrence of GDM in subsequent pregnancies is documented in two thirds of 
the patients.(80) Early breast feeding is always encouraged in women with 
GDM to prevent hypoglycemia in newborns and to reduce the childhood 
obesity. 
Counseling before pregnancy and multidisciplinary management are important 
for good pregnancy outcomes. The main aim in the diet modification is to 
avoid peak values in blood glucose levels. It can be done by the use of 
carbohydrate sources with slow release and splitting carbohydrate intake into 
three meals and snacks throughout the day  
Intake of foods with more fibers like fruits, vegetables and whole grains will 
decrease the risk of GDM. Blood sugar samples are used to determine HbA1C 
regularly that gives an idea of level of blood sugar control over a long period 
of time. (28)  
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CONTRACEPTION: 
Education of patients with GDM should always include the need for family 
planning practices to ensure good glycemic status from starting of any 
subsequent pregnancies. 
Women with prior gestational diabetes have many options in contraception and 
can have any form of contraception, as the same guidelines recommended in 
other women.  
Barrier methods like condoms, cervical cap, diaphragm, and spermicides lack 
systemic side effects and they have no influence on glucose metabolism. So 
they are used safely in women with GDM. The main drawback is higher 
failure rate and high motivation of the patient and their partner.  
Intrauterine devices (IUCD) are ideal contraception in women with prior 
GDM. They are very effective and reversible method without causing any 
disturbances in glucose metabolism. According to the Medical Eligibility 
Criteria for Contraceptive Use in 2004 report by World Health Organization 
prior GDM is not a contraindication for insertion of IUCD. (81) 
Evidence from clinical studies support the use of low dose combined oral pills 
(COC) in women with prior GDM. Formulation of COC which contains 
ethinyl estradiol in lowest dose and progestins are prescribed in women with 
GDM like same precautions and recommendations as like in healthy women. 
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The risks or benefits of non oral combination methods are considered similar 
to that of COC and there is no specific data relating to gestational diabetes.(82) 
The rate of subsequent diabetes is not increased by the use of oral 
contraceptives. Progestins only pills are not used as the first choice of 
contraception in lactating mothers. (81) 
Lastly sterilization is offered in the women who have completed their child 
bearing mainly to the parous women. 
LONG TERM CONSEQUENCES OF GDM: 
In most cases, GDM resolves following the delivery, but may recur in 
subsequent pregnancy, usually at progressive earliest gestational weeks. 
Women with GDM have increased risk of developing type 2 diabetes 
following delivery. Factors that causes increased risk of progression to type 2 
diabetes mellitus includes gestational age at time of diagnosis of GDM, level 
of blood glucose control at diagnosis , at the first assessment in postpartum 
period, impairment of function in beta cells, obesity and further pregnancy.  
Progression to diabetes also depends on the ethnicity. Women who need 
insulin to control blood sugar levels have a 50% risk to develop diabetes 
within next five years of life.(75) Women with more than two pregnancies and 
obesity are also other risk factors. The risk varies depending on the ethnicity, 
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diagnostic criteria and duration of follow up of the patients. The risk is higher 
in the first five years, after that it reaches a plateau level. 
Infants born to the women with gestational diabetes are more prone to develop 
childhood and adult obesity and have increased risk for developing glucose 
intolerance and type 2 diabetes mellitus in their later life. (83) The risk is related 
to level of increased blood sugar values in the mother. (84) 
Women who had GDM are provided appropriate health education on reducing 
cardiovascular risk factors, as the mortality and morbidity from the premature 
heart disease is increased.  
The importance of weight maintenance and exercise is stressed for both 
cardiovascular protection and delaying the onset of type 2 diabetes mellitus 
and impaired glucose tolerance. The greatest protective effect of exercise in 
maintaining the glucose tolerance is conferred on the individuals at greatest 
risk. 
 
 
 
52 
 
 
 
 
       MATERIALS AND         
              METHODS 
 
 
 
 
 
 
 
 
53 
 
MATERIALS AND METHODS  
Aims and objectives 
-  To determine perinatal outcome in relation to maternal fasting and 
postprandial (2 hours) blood sugar control in gestational diabetes mellitus.  
- Perinatal outcomes included are macrosomia, Respiratory distress 
syndrome, hypoglycemia, seizures, hyperbilirubinemia, NICU admission, 
Anomaly, IUD, Stillbirth, perinatal injury, perinatal mortality. 
Study place 
The study was conducted at the Institute of Social Obstetrics, Government 
Kasturba Gandhi Hospital, Attached to Madras Medical College, Chennai. 
Study Design 
This was prospective study / observational study. 
Study Period 
The study was conducted for a period of one year from December 2012 to 
November 2013. 
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Participants 
The study group consisted of 150 patients after considering the exclusion and 
inclusion criteria. 
Inclusion criteria 
- Singleton pregnancy 
- Cut off  value for FBS is < 95mg/dl and PPBS (2 hours) is <120 mg/dl 
- Blood sugar taken at the time of diagnosis of GDM, 2nd trimester and 3rd 
trimester towards term.  
- Age < 35 years 
- Primi and multigravida 
- Antenatal GDM mothers on meal plan and insulin 
- Cephalic presentation 
- Women booked and immunized in KGH 
- Women with regular antenatal visits 
- Neonatal outcomes are observed for macrosomia, hypoglycemia, 
respiratory distress syndrome, seizures, hyperbilirubinemia, anomaly, 
stillbirth, IUD, perinatal morbidity and mortality. 
Exclusion criteria 
- Overt diabetes 
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- Abnormal presentation 
- Preterm and PROM 
- Associated medical disorders like hypothyroidism and hypertension 
- Multiple pregnancy and IUGR 
- First visit to KGH 
- Normal antenatal mothers without GDM 
Method of study  
All antenatal mothers attending the OPD are subjected to 75 gm of glucose 
challenge test in first, second and third trimester. If GCT is elevated above 
140 mg/dl, these patients are advised meal plan for 2 weeks. Fasting and 
postprandial blood sugars (2hours) are done.  
If FBS and PPBS are normal, the patient is labeled as GDM on meal plan. If 
fasting > 96 mg/dl and 2-hr postprandial blood sugar > 121 mg/dl, insulin is 
started along with diet modification and patient is labeled as GDM on insulin. 
In patients with GDM on insulin FBS and PPBS are taken according to the 
blood sugar control and the dose of insulin is adjusted. In case of GDM on 
meal plan, FBS and PPBS are taken every 15 days. 
If the GCT is normal is 1st trimester, it is repeated again in 2nd trimester at 24 
weeks and 3rd trimester in 32 weeks. If it is normal in 2nd trimester, it is again 
done in 3rd trimester. 
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Follow up the patients were done antenatally with fasting and postprandial 
blood sugar values and the dose of insulin is adjusted according to the blood 
sugar values. The patient is then followed intrapartum. Fetal outcomes are 
evaluated. Neonatal outcomes included are macrosomia, hypoglycemia, 
respiratory distress syndrome, seizures, hyperbilirubinemia, anomaly, 
stillbirth, IUD, perinatal morbidity and mortality. 
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                                          RESULTS 
Total no. of cases : 150 
  GDM on treatment 
A total of 150 patients were included in the study. In this 63 patients were on meal 
plan, 79 patients were on insulin, 6 patients initially on meal plan  were converted 
to insulin, 2 patients initially on insulin were converted to meal plan. 
    Table 1 
GDM No. of patients % 
Meal plan 63 42.0 
Insulin with meal plan 79 52.7 
Meal plan converted  to insulin 6 4.0 
Insulin converted to insulin 2 1.3 
Total 150 100 
 
Figure 1 
 
No.of patients
meal plan
insulin+mealplan
meal plan to insulin
Insulin to meal plan
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Age distribution 
Table 2: Shows the age distribution in GDM .60% of the patients were in age 
group of 26 to 30 years 
Table 2 
Age No.of patients % 
20 - 25 26 17.3 
26 -30 90 60 
>30 34 22.7 
Total 150 100 
 
Figure 2 
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Table 3: Shows the relation of age with GDM. 
Age in 
years 
GDM on treatment Total P Value 
 
.006 
 Meal 
plan 
Insulin 
and 
meal 
plan 
Meal 
plan to 
insulin 
Insulin 
to meal 
plan 
20 - 25 N
o. 
17 7 1 1 26 
% 65.4 26.9 3.8 3.8  
26 – 30 N
o. 
40 45 4 1 90 
% 44.4 50 4.4 1.1  
>30 N
o. 
6 27 1 0 34 
% 17.6 79.4 2.9 0  
Total N
o. 
63 79 6 2 150 
% 42 52.7 4 1.3  
 
P <0.05, there was significant association between age and onset of GDM. 
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BMI DISTRIBUTION  
Table 4: Shows BMI distribution in GDM. 59.3% of patients were in BMI of 
range 25 - 30 
BMI No. of patients % 
18-24 39 26.0 
25-30 89 59.3 
>30 22 14.7 
Total 150 100.0 
 
Figure 3 
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Table 5: Shows the relation of BMI with GDM. 
BMI  GDM on treatment  Total P 
Value 
 
.000 
Meal 
plan 
Insulin 
and meal 
plan 
Meal plan 
to insulin 
Insulin 
to meal 
plan 
18-24 No. 39 0 0 0 39 
% 100.0 0 0 0  
25-30 No. 24 59 4 2 89 
% 27.0 66.3 4.5 2.2  
>30 No. 0 20 2 0 22 
% 0 90.9 9.1 0  
Total No. 63 79 6 2 150 
% 42.0 52.7 4.0 1.3  
 
P < 0.05, there was significant association between BMI and GDM. 
 
 
 
 
 
 PARITY DISTRIBUTION
34.7% of the patients were primi and 65.3% were multi
Table 6 
P > 0.05, there was no significant association between parity
Figure 4 
 
Parity  GDM on treatment
Meal 
plan 
Insulin 
with meal 
plan
Primi No. 29 20
% 55.8 38.5
Multi No. 34 59
% 34.7 60.2
Total No. 63 79
% 42.0 52.7
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 and GDM
 
Primi
Multi
PARITY
  Total 
 
Meal 
plan  to 
insulin 
Insulin to 
meal plan 
 2 1 52 
 3.8 1.9  
 4 1 98 
 4.1 1.0  
 6 2 150 
 4.0 1.3 
 
. 
% P 
Value 
 
.077 
34.7 
 
65.3 
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FAMILY HISTORY OF DIABETES 
Family history of diabetes was present in 24.7% of the patients. 
Table 7: shows the family history of diabetes in patients with GDM. 
Family 
History 
 GDM on treatment Total % P Value 
 
.000 
Meal 
plan 
Insulin 
and meal 
plan 
Meal plan 
to insulin 
Insulin to 
meal plan 
Present No. 3 30 3 1 37 24.7 
% 8.1 81.1 8.1 2.7 
  
 
P < 0.05, there was significant association between presence of family history of 
diabetes and the occurrence of GDM. 
Figure 5 
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PREVIOUS GDM 
Previous history of GDM was present in 27.3% of cases. 
 Table 8 
 
Previous 
GDM 
 GDM on treatment Total % P 
Value 
 
.000 
 Meal 
plan 
Insulin 
and meal 
plan 
Meal 
plan to 
insulin 
Insulin 
to meal 
plan 
Present No. of 
patients 
1 37 3 0 41 27.3 
% 2.4 90.2 7.3 0   
 
P < 0.05, there was significant association between the presence of GDM in 
previous pregnancy and the occurrence of GDM in present pregnancy. 
Figure 6 
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98% of GDM were detected in 2
Table 9: Shows the diagnosis of GDM according to 
Diagnosis 
1st  trimester 
2nd trimester 
3rd trimester 
Total 
 
Figure 7 
 
Diagnosis at trimester 
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nd
 trimester. 
trimester of pregnancy.
No. of patients % 
1 0.7 
147 98.0 
2 1.3 
150 100.0 
1st trimester 
2nd trimester 
3rd trimester
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Risk factors with GDM  
TABLE 10: shows the number of risk factors and the occurrence of GDM. 
No. of 
risk 
factors 
 GDM on treatment P Value 
 
.000 
 
Meal 
plan 
Insulin 
and 
meal 
plan 
Meal 
plan to 
insulin 
Insulin 
to meal 
plan 
Total 
0 No. 17 4 1 0 22 
% 77.3 18.2 4.5 0  
1 No. 42 29 1 2 74 
% 56.8 39.2 1.4 2.7  
2 No. 4 20 1 0 25 
% 16 80 4 0  
3 No. 0 8 2 0 10 
% 0 80 20 0  
4 No. 0 11 1 0 12 
% 0 91.7 8.3 0  
5 No. 0 7 0 0 7 
% 0 100 0 0  
Total No. 63 79 6 2 150 
% 42 52.7 4.0 1.3  
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P < 0.05, there was significant association between number of risk factors and 
the occurrence of GDM. The risk factors included are 1) age > 25 years 2) BMI 
>30 3) family history of diabetes 4) previous GDM 5) gestational hypertension. 
Figure 8 
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FBS & PPBS at time of diagnosis 
At the time of diagnosis 60.7% of patients had FBS < 95 mg/dl and 46% of 
patients had PPBS < 120 mg/dl. 
Table 11 
FBS (in mg/dl) No. of patients % 
<95 91 
 
60.7 
96-119 50 33.3 
>120 9 6.0 
PPBS (in mg/dl) No. of patients % 
<  120 69 46.0 
121-159 26 17.3 
160-199 52 34.7 
>  200 3 2.0 
 
Figure 9 
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FBS and PPBS in 2nd trimester 
Blood sugar values FBS < 95 mg/dl was seen in 85.3% and PPBS < 120 mg/dl 
was seen in 43.3% of cases 
Table 12 
 
2 cases are not detected in 2nd trimester because of normal value of GCT; 
elevated GCT was detected in 3rd trimester. 
 
 
 
FBS (in 
mg/dl) 
No. of 
patients 
% PPBS (in 
mg/dl) 
No. of 
patients 
% 
<95 128 85.3 <  120 65 43.3 
96-119 18 12.0 121-159 51 34.0 
>120 2 1.3 160-199 31 20.7 
   >  200 1 0.7 
Total 148 98.7 Total 148 98.7 
Missing 2 1.3 Missing 2 1.3 
Total 150 100 Total 150 100 
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FBS & PPBS in 3rd trimester   
Ideal blood sugar values FBS < 95 mg/dl was seen in 99.3% and PPBS < 120 
mg/dl was seen in 72.7% of cases by effective treatment. 
Table 13 
FBS (in mg/dl) No. of patients % 
<95 149 99.3 
96-119 1 0.7 
PPBS (in mg/dl) No. of patients % 
<  120 109 72.7 
121-159 36 24.0 
160-199 5 3.3 
 
There was no case with FBS > 120 mg and PPBS > 200 mg. 
Figure 10 
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MODE OF DELIVERY 
      The percentage of patients who had caesarean section was 42% (Both LSCS 
and repeat LSCS), the most common indication being Previous LSCS and CPD.  
Table 14 
Mode of delivery No. of patients % 
Labor natural 82 54.7 
Instrumental delivery 5 3.3 
LSCS 34 22.7 
Repeat LSCS 29 19.3 
Total 150 100.0 
 
INDICATION FOR LSCS 
Table 15 
Indication No. of patients % 
Fetal distress 9 14.3 
CPD 14 22.2 
Failed induction 11 17.5 
Previous LSCS 29 46.0 
Total 63 100.0 
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Adverse neonatal outcomes 
Table 16: Shows the number of adverse neonatal outcomes in GDM. 
Adverse neonatal 
outcomes 
GDM on treatment Total P Value 
 Meal 
plan 
Insulin 
and 
meal 
plan 
Meal 
plan to 
insulin 
Insulin 
to 
meal 
plan 
Macrosomia No. 0 13 0 0 13 
 
.005 % 0 100 0 0  
 
RDS 
No. 0 5 0 0  
5 
 
.199 
% 0 100 0 0  
 
Hypoglycemia 
No. 0 9 0 0 9  
.035 % 0 100 0 0  
Hyperbilirubinemia No. 0 5 0 0 5  
.199 % 0 100 0 0  
IUD No. 0 1 0 0 1  
.824 
 
% 0 100 0 0  
Perinatal morbidity No. 0 2 0 0 2  
.610 % 0 100 0 0  
NICU Admission 
> 3 days 
 
No. 1 17 0 0 18  
.002 % 5.6 94.4 0 0 
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The percentage of cases presented with Macrosomia was 8.7%, RDS 3.3%, 
hypoglycemia 6%, hyperbilirubinemia 3.3%, IUD 0.7%, perinatal injury 1.3%, 
NICU admission requiring more than 3 days of admission was 12%. There were 
no cases of seizures (due to hypoglycemia or hypocalcemia ), still birth, 
anomaly, perinatal mortality. 
P < 0.05, there was significant association between GDM and occurrence of 
macrosomia, hypoglycemia and NICU admission > 3 days in neonates. P >0.05, 
there was no significant association between GDM and the occurrence of RDS, 
hyperbilirubinemia, IUD, perinatal morbidity  
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Risk factors with neonatal outcomes 
Table 17 compares the number of risk factors in the mother such as 1)age > 25 
years 2) BMI >30 3) family history of diabetes  4)previous GDM 5) gestational 
hypertension with the occurrence of adverse neonatal outcomes. 
Table 17 
No. of risk 
factors 
Adverse Neonatal outcomes P Value 
 
.265 
No. % 
0 0 0 
1 11 14.9 
2 3 12 
3 2 20 
4 3 25 
5 2 28.6 
Total 21 14 
 
P > 0.05, there was no significant association between number of risk factors 
and adverse neonatal outcome.  
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Fasting blood sugar  
Table 18: Shows the fasting blood sugar values at the time of diagnosis, at 2nd 
trimester, 3rd trimester 
FBS (in 
mg/dl) 
At time of 
diagnosis 
At 2nd trimester At 3rd trimester 
 
No. of 
patients 
% No. of 
patients 
% No. of 
patients 
% 
<95 91 
 
60.7 128 85.3 149 99.3 
96-119 50 33.3 18 12.0 1 0.7 
>120 9 6.0 2 1.3 0 0 
Total - - 148 98.7 - - 
Missing - - 2 1.3 - - 
Total 150 100 150 100 150 100 
 
2 cases are not detected in 2nd trimester because of normal value of GCT; 
elevated GCT was detected in 3rd trimester. 
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FBS and adverse neonatal outcome 
Table 19: Shows adverse neonatal outcomes according to the level of fasting 
blood sugar control. 
FBS (in 
mg/dl) 
Adverse neonatal outcomes 
At time of diagnosis In 2nd trimester In 3rd trimester 
 No. % No. % No.     % 
< 95 5 5.5 15 11.7 20 13.4 
96-119 10 20 4 22.2 1 100 
> 120 6 66.7 2 100 0 100 
P 
Value 
 
.000 
 
.001 
 
.013 
 
As the fasting blood sugar increases, percentage of adverse neonatal outcome 
increases.  Since P <0.05, there was significant association between FBS and 
the occurrence of adverse neonatal outcomes. 
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Post prandial blood sugar 
Table 20: Shows the postprandial blood sugar values at the time of diagnosis, at 
2nd trimester, 3rd trimester. 
PPBS (in mg/dl) At time of 
diagnosis 
In 2nd trimester In 3rd trimester 
 No. of 
patients 
% No. of 
patients 
% No. of 
patients  
% 
<  120 69 46.0 65 43.3 109 72.7 
121-159 26 17.3 51 34.0 36 24 
160-199 52 34.7 31 20.7 5 3.3 
>  200 3 2.0 1 0.7   
Total   148 98.7   
Missing   2 1.3   
Total 150 100 150 100 150 100 
 
2 cases are not detected in 2nd trimester because of normal value of GCT; 
elevated GCT was detected in 3rd trimester. 
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PPBS and adverse neonatal outcomes 
Table 21: Shows adverse neonatal outcomes according to the level of 
postprandial blood sugar control. 
 Adverse neonatal outcomes 
At time of 
diagnosis 
In 2nd trimester In 3rd trimester 
PPBS (in mg/dl) No. Percent No. Percent No. Percent 
<  120 4 5.8 5 7.7 6 5.5 
121-159 2 7.7 5 9.8 12 33.3 
160-199 12 23.1 10 32.3 3 60 
 
>  200 
3 100 1 100 0 100 
P Value .000 
 
.001 .000 
 
As the postprandial blood sugar increases, Percentage of adverse neonatal 
outcome increases. P < 0.05, there was significant association between PPBS 
and occurrence of adverse neonatal outcomes. 
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                                               DISCUSSION 
Glucose intolerance in pregnancy can be of varying severity depending on risk 
factors and the glycemic control. Therefore early diagnosis, adequate treatment 
and follow up are essential in managing the patients with GDM. 
WHO criteria 75 gm of glucose load and 2hour plasma glucose was able to 
correctly identify the patients with GDM.(8) In present study WHO criteria was 
followed for screening and patients with GDM were detected. ACOG criteria 
was used for cut of values to maintain normal blood sugar  FBS < 95mg/dl and 
PPBS < 120 mg/dl  
RISK FACTORS  
According to ACOG criteria, age > 25 years and BMI > 30 were considered as 
high risk factor. In present study, 82.7% patients were > 25 years and 14.7% of 
the patients had BMI > 30. Since P value < 0.05, it was concluded that there 
were significant association between age and BMI with GDM since P value < 
0.05.  
Multiparous women (65.3%) were more affected than primigravida (34.7%). 
Since P value >0.05, there was no significant association between parity and 
occurrence of GDM. 
In a study by Catherin et al (2009) family history of diabetes mellitus were 
present in 35% of cases. In present study family history was present in 24.7% of 
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cases .Since P value is < 0.05, there was a significant association between 
family history of diabetes mellitus and occurrence of GDM in pregnancy.   
In a study by Catherin et al (2007) (80) history of gestational diabetes in 
previous pregnancy was associated with occurrence of GDM in present 
pregnancy. In present study, previous history of GDM was present in 27.3% of 
cases. There was a significant association between previous GDM history with 
onset of GDM in index pregnancy since P value < 0.05. In study by Yogev et al 
(85) the incidence of preeclampsia in GDM with good glycemic control was 
7.8%, in present study it was 8.7% of cases. 
There was a significant association between number of risk factors and the 
occurrence of GDM.  
But there was no significant association between the number of risk factors and 
the occurrence of adverse neonatal outcomes. 
GDM screening should be started in first trimester. (8) Early detection and blood 
sugar control results in better fetal outcome. In present study 98% cases were 
detected in 2nd trimester, 0.7% and 1.3% of cases were detected in 1st trimester 
and 3rd trimester respectively. 
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OPERATIVE DELIVERY   
                                OPERATIVE DELIVERY 
AUTHOR Percentage 
Evers et al [86] 44 
Yogev et al [87] 30 
Present study 42 
 
The percentage of patients who had caesarean section was 42% (Both LSCS and 
repeat LSCS), the most common indication being Previous LSCS (46%) and 
CPD (22.2%). 
NEONATAL OUTCOMES: 
Jacques et al found the incidence of NICU admission was 16%, respiratory 
distress syndrome was 6.9%, hypoglycemia 3.2%. Evers et al (86) found the 
incidence of respiratory distress syndrome to be 15%, hyperbilirubinemia as 
25%, macrosomia as 45%. In study by Casson et al the incidence of still birth 
was 2.5%. A study by priyanka et al (88) showed the incidence of macrosomia 
was 18%, NICU admission 27.2%, hypoglycemia 9%, hyperbilirubinemia 12%. 
In a study by Preeti et al showed the incidence of respiratory distress syndrome 
was 3.23%, perinatal inhury was 1.4%, macrosomia was 7%. 
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In the present study the incidence of macrosomia was 8.7%, RDS 3.3%, 
hypoglycemia 6%, hyperbilirubinemia 3.3%, IUD 0.7%, perinatal injury 1.3%, 
NICU admission requiring more than 3 days of admission was 12%.  
P < 0.05, there was a significant association between GDM and the occurrence 
of macrosomia, hypoglycemia and NICU admission > 3 days in neonates. P 
>0.05, there was no significant association between GDM and the occurrence of 
RDS, hyperbilirubinemia, IUD, perinatal morbidity. 
There were no cases of seizures (due to hypoglycemia or hypocalcemia ), still 
birth, anomaly, perinatal mortality. 
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                                         SUMMARY 
Total of 150 patients were included in the study. Of which 63 was on meal plan, 
79 was on insulin and meal plan, 6 was on meal plan converted to insulin, 2 was 
on insulin converted to meal plan. 
Age >25 years was the single most important risk factors. There was a 
significant association between age and the occurrence of GDM. 
BMI > 30 was also a risk factor for GDM. There was a significant association 
between BMI and the occurrence of GDM. 
There was a significant association between the presence of family history of 
diabetes and the occurrence of GDM in the index pregnancy.  
There was also a significant association between the presence of GDM in 
previous pregnancy and its occurrence in index pregnancy. 
History of PIH was also a risk factor associated with GDM. 
So to conclude there was a significant association between the number of risk 
factors and the occurrence of GDM. 
Most cases of GDM were detected in 2nd trimester of pregnancy. 
Ideal fasting blood sugar level of < 95 mg /dl was seen in 60.7% of patients at 
the time of diagnosis, with treatment effective blood sugar control was achieved 
in    99.3 % of patients. Ideal post prandial blood sugar level of < 120 mg/dl was 
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seen in 46 % of patients at the time of diagnosis; with treatment effective blood 
sugar control was achieved in72.7 % of patients. 
Caesarean section was done in 42% of patients (Both LSCS and repeat LSCS), 
the most common indication being Previous LSCS (46%) and CPD (22.2%).  
The percentage of cases presented with Macrosomia was 8.7%, RDS 3.3%, 
hypoglycemia 6%, hyperbilirubinemia 3.3%, IUD 0.7%, perinatal injury 1.3%, 
NICU admission requiring more than 3 days of admission was 12%. There were 
no cases of seizures ( due to hypoglycemia or hypocalcemia ), still birth, 
anomaly, perinatal mortality. 
There was a significant association between GDM and the occurrence of 
macrosomia, hypoglycemia and NICU admission > 3 days in neonates and there 
was no significant association between GDM and the occurrence of RDS, 
hyperbilirubinemia, IUD, perinatal morbidity. 
There was a significant association between FBS and PPBS and the occurrence 
of adverse neonatal outcomes. 
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                                        CONCLUSION 
There is relationship between fasting and postprandial blood sugar values and 
neonatal outcomes. Early diagnosis and treatment of gestational diabetes with 
adequate antenatal care are essential to reduce the adverse neonatal outcomes. 
So universal screening in early gestation is recommended. Early detection of 
GDM and adequate blood sugar control is done to reduce the adverse neonatal 
outcomes. There is no relationship between the number of risk of risk factors 
and adverse neonatal outcomes. But when the number of risk factors increases 
the risk for GDM is increased. 
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                                                               PROFORMA 
 
Name :                                        Age :                            I.P.No.:  
 
                                      
Address:                                     SES :                            Ht:  
                                                   Literacy:                      Wt:   
 
G ravida                                   Para                                Live    
Abortion                                  LMP                              EDD  
 
Menstrual History :   
                                                                                      DOA :  
Marital History:                                                            DOD : 
                                                                                      
Obstetric History :    Previous pregnancy 
-   H/O GDM in previous pregnancy   
-  Previous FTND or Previous LSCS 
                                 Present Pregnancy 
-  H/ O PIH              
Past History  :       
Family History :  Family history of diabetes mellitus.    
                                                              
GENERAL EXAMINATION  
Built & Nourishment                                        Ht : 
Pallor                                                                Wt : 
Pedal edema                                                     BMI : 
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CVS & RS  
P/A  
 
INVESTIGATIONS  
 
Hb%     
                                                   
Urine : Alb                                            
            Sugar  
            Deposits      
 
Glucose challenge test (GCT) : In 1st , 2nd and 3rd trimester ( diagnosis of GDM 
done in which trimester ) 
 
Blood sugar levels 
 
Blood sugar levels At time of 
diagnosis 
In 2nd trimester In 3rd trimester 
FBS    
PPBS    
 
 
USG 
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GDM  treatment  
- On meal plan 
- On insulin and meal plan 
- Meal plan converted to insulin  
- Insulin converted to meal plan 
 Maternal factors 
Mode of delivery 
- Labour natural  
- Instrumental delivery 
- LSCS 
- Repeat LSCS 
 
Caesarean section : Indication 
   
NEONATAL OUTCOMES  
-  Macrosomia              - Respiratory distress syndrome 
-  Hypoglycemia           - Seizures 
- Hyperbilirubinemia     - NICU admission 
- Anomaly                     - IUD 
- Stillbirth                      - Perinatal injury 
- Perinatal mortality 
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        ABBREVIATIONS 
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                         ABBREVIATIONS 
GDM         -   Gestational Diabetes Mellitus 
NICU        -   Neonatal Intensive Care Unit 
IUD           -   Intra Uterine Death 
ADA         -   American Diabetic Association 
FBS          -   Fasting Blood Sugar 
PPBS        -   Post Prandial Blood sugar 
ACOG      -   American College of Obstetrics and Gynaecology 
PIH          -   Pregnancy Induced Hypertension 
WHO       -   World Health Organization 
Hb            -   Hemoglobin 
GLUT     -   Glucose Transporters 
UTI         -   Urinary Tract Infection 
GCT       -   Glucose Challenge Test 
OGTT    -   Oral Glucose Tolerance Test 
RDS       -   Respiratory Distress Syndrome 
TTN       -   Transient Tachypnea of Newborn 
FDA       -   Food and Drug Administration 
IUCD     -   Intra Uterine Device 
COC      -   Combined Oral Contraceptives 
105 
 
MNT      -   Medical Nutrition Therapy 
CVS       -   Cardio Vascular System 
CNS       -   Central Nervous System 
RS          -   Respiratory System 
BMI        -   Body Mass Index 
PROM    -  Pre labor Rupture Of Membrane 
LSCS      -   Lower Segment Caesarean Section 
CPD        -   Cephalo Pelvic Disproportion 
FTND     -   Full Term Normal Delivery 
LMP       -   Last Menstrual Period 
EDD       -   Expected Date of Delivery 
DOA      -   Date Of Admission 
DOD      -   Date Of Delivery 
SES       -   Socio Economic Status 
USG     -   Ultra Sono Gram 
Ht         -   Height 
Wt        -   Weight 
P/A     -  Per Abdomen 
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